Supplemental Tables 1-8 from Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft

Table S1. Expanded HSPC engraftment into mouse cohorts Table S2. Human immune cell presence in HM tissues Table S3a. CUHM003 mutations present at diagnosis b. Additional CUHM003 mutations present at progression c. CUHM005 mutations present at diagnosis d. Additional CUHM005 mutations present at progression Table S4. Enrichment of immunity-related genes in patient and HM tumors Table S5a. Genes expressed only in the CUHM003 patient and mHM model b. Genes expressed only in the CUHM003 patient and aHM model c. Genes expressed only in the CUHM005 patient and mHM model d. Genes expressed only in the CUHM005 patient and aHM model Table S6. Changes in cancer pathway GSEA expression in patients, their NSG, mHM, and aHM models Table S7. Changes in GSEA hallmark expression between mouse models Table 8a. Genes differentially expressed in CUHM003 after PD1 treatment b. Genes differentially expressed in CUHM005 after PD1 treatment